|
Post by kc on Aug 30, 2017 14:13:39 GMT -5
wash rinse & repeat..
|
|
|
Post by kc on Aug 30, 2017 13:53:15 GMT -5
Something is up. I have a new view using ML system and see a lot of "INTER MARKET SWEEP ORDER" Showing up. I had not ever seen or heard of this but here is what IB says its about.
ibkr.info/node/1734
Intermarket Sweep
overview:
An intermarket sweep order is generally a large quantity limit order that is sent to multiple exchanges simultaneously. The trader submitting this type of order is required to fulfill Regulation NMS order protection obligations and exchange rules by simultaneously sending orders to market centers with better prices than the defined order limit.
Background:
Traders may see, on occasion, execution prices reported to time and sales that are at price levels through an order that they may have had working at the time. Some time and sales service providers reflect these prints with a special designation (intermarket sweep). The TWS software does not display these designations, therefore, it may appear as if a order was due an execution when it may not have been.
This article is being written in attempt to assist traders in understanding intermarket sweep transactions.
When an intermarket sweep order is being executed, only the inside quote (NBBO) at each available exchange is "protected". This means that orders resting on an exchange at prices that are inferior to the best bid or ask prices at the time of the intermarket sweep print are not considered to be "protected" and may be traded through.
Example: An order is submitted in the pre market to sell at a price of 40.80 and is sent to exchange A. The best offer price on exchagne A is 40.63. Exchange B receives an intermarket sweep order to buy 800 shares of the stock at a limit price of 40.88. The best offer price on exchange B is 40.88
The trader that enters the intermarket sweep order would be required to fulfill their Regulation NMS requirement by executing the maximum available quantity on exchange A at 40.63 and then may execute the balance of the order on exchange B at 40.88 even though it is at a price that is inferior to the 40.80 order resting in the book on exchagne A. The 40.80 price is not the inside quote and is therefore not "protected" in terms of the balance of the sweep order executing at exchange B at a price of 40.88.
A wealth of information is available on the web regarding intermarket sweep orders and SEC regulation NMS. The following are some links that may be useful in terms of providing additional information on these topics; SEC Regulation NMS Rule June 29, 2005
|
|
|
Post by kc on Aug 30, 2017 13:11:32 GMT -5
Smoking hot rate to borrow shares at Fidelity....... Kaboom..... 99% you better call now and lock in that rate.
|
|
|
Post by kc on Aug 30, 2017 11:53:30 GMT -5
question: Did SNY or MNKD get awarded any government contracts while they were partners? I understand it's a small contract, but a gov. award non the less. It's a very positive sign! They have had other awards that have been posted on this board before. I don't want to minimize the award but its in the normal course of business and Mike and the team have had a lot of them that we will never know about.
|
|
|
Post by kc on Aug 30, 2017 11:36:39 GMT -5
Nice award but a small contract amount. I would guess that no PR is announced since its just in the course of normal daily business. It just shows that the company is doing business.
|
|
|
Post by kc on Aug 28, 2017 20:45:12 GMT -5
That's a very interesting and creative way to look at the prospect for a higher share price, cjc! I like it very much. Of course, I'm far too pessimistic to ever come up with that myself. I'm wondering what will have had to occur for us to be viewed in that light - what is that, a $2 billion+ market cap or so? Big foreign sales bringing in revenue instead of further debt or equity financing would do the trick! Heck, an Oprah Winfrey-type (likely only Oprah) getting on board might do it! My number one hope is still a buyout at about double whatever our current share price is (so long as the share price doesn't head materially south from here). Gotta love the rally we've been enjoying of late! You've been on this board for 4 years and your "Number One" hope is a buyout at ~ $3.40 Post RS / $ 0.68 Pre RS? Are you Long or Short? Ok Newbie Omega..... Baba is not to be questioned. I happen to agree with her as we all have been here for a long time and have seen the downward momentum and the pain of buying down down down. I would be very pleased with a buyout in the $20.00 range but realistically if we got $10.00 and the product lived on with a well capitalized Pharma most of us would be very happy. I for one had about 130,000 shares of the pre-split stock. So I know that Baba and others have a lot of skin in the game. Call me a big time loser as I also now have about 60,000 post split shares. Yep I still believed in Afrezza and the MannKind team to turn the company around. I have met Mike C. I have communicated and met several of the sales & marketing team and still believed that they could turn the company around. So I bought more. So hopefully I will not be a even bigger loser.
|
|
|
Volume too
Aug 26, 2017 21:56:39 GMT -5
via mobile
Post by kc on Aug 26, 2017 21:56:39 GMT -5
Takeda Would be an interesting partner or more. That would open up the far east especially Japan. They have products in diabetes treatment. But also have failures.
|
|
|
Post by kc on Aug 7, 2017 21:54:37 GMT -5
Only a white knight looking to do something good for humanity would give MNKD the $200M they put into the plant. At the same time getting in on the greatest advance in diabetes care in 95 years probably has Buffet's attention. I think Mike can make that elevator pitch. Its like peanut butter and jelly. Buffet's got $100B he needs to do something with and MNKD needs a couple hundred $Million. Mike would be doing Buffet the favor by giving him this opportunity. Buffet is letting the Bill Gates foundation give away his money. Doubtful if this gets past the first step You didn't hear Gates foundation buys all the outstanding shares of mankind and gives Afrezza aWay to cure diabetes
|
|
|
Post by kc on Aug 7, 2017 21:32:15 GMT -5
They had better have an ace up their sleeve because these financial numbers truly, truly suck. The cost of inventory expired due to expiration date exceeds the revenue. Wow! "The cost of inventory expired due to expiration date exceeds the revenue. " Although this is not good, it was to be expected. In reality it doesn't matter because it is a paper write-off. Its effect on cash was some time ago and it is cash that matters now. Cash and scripts have to be the real focus. Ignore the other noise, both good and bad. It's sad that they can't give the expired but still good product to some charitable organization. And I guess they could not do that.
|
|
|
Post by kc on Aug 7, 2017 15:53:50 GMT -5
It is what it is. Until there are some sales there will be no progress and perhaps bankruptcy. I'm a big boy and understand the risk. Not fun but there is not much we can do until the product sells or the company sell to another Pharma.
|
|
|
Post by kc on Aug 7, 2017 9:52:19 GMT -5
What surprise for today? There will be none since its all based on Sales and they have ben slow to build up. I just hope we can continue to stay above $1.00. Maybe they will have some good news but I am not holding my breath.
I believe that Management is working hard but its a struggle when you are boot strapped.
|
|
|
Post by kc on Aug 7, 2017 9:47:28 GMT -5
You all kept asking what was going on with both party's working together. I think they are trying to create a Paradigm shift in treatment that can be done easier than at a doctors office but perhaps at a clinic like VEDEX. If their trial turns out the way they want it to then they can sell it as a solution to diabetes clinics that might be online monitored or set up in a Drugstore type clinic. Make treatment more accessible to the masses or even treating Pre-Diabetes with giving the pancreas a break.
Insulin for a type two if monitored more precisely could be mealtime only.
Smart move on MannKind's part as they get more visibility being tied to One-Touch. Jeff is a much more Raw marketer than MannKind and we need that visibility he brings.
|
|
|
Post by kc on Aug 6, 2017 17:00:57 GMT -5
VDEX put out the tweet a few minutes ago. Good messaging by the founder of VDEX.
|
|
|
Post by kc on Jul 27, 2017 23:54:40 GMT -5
Every member of Congress and the Senate have a health care liaison aid. It's just another way of informing them of the existence of a great product that aids diabetics that is not very visible to the general public. To each their own but it would not hurt because they get calls every day in their office by sick people I'm sure many of them with diabetes. Perhaps even some members of their staff or congressman/Senator also have diabetes
|
|
|
Post by kc on Jul 27, 2017 23:15:37 GMT -5
Hope this will make the shorts to rethink about their position and the future MNKD partners ink a deal with MNKD faster. The waiting of a manful short squeeze seems endless ... It won't!
|
|